FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:964-966 August 28, 2008 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by San Miguel, J. F. PubMed Citation

In this issue of the Journal, San Miguel et al.¹ describe the benefit of combining bortezomib with melphalan plus prednisone, as compared with melphalan plus prednisone alone, as initial therapy for patients with myeloma who are not candidates for hematopoietic stem-cell transplantation. The critical comparative statistics leave no doubt that combination therapy with bortezomib is superior to melphalan plus prednisone alone. But how does this clear-cut evidence inform treatment decisions? To effectively apply these findings to clinical practice in the appropriate setting, we need prospective comparisons with other available options, valid uniform standards for those comparisons, and greater consideration of . . . [Full Text of this Article]

Source Information

From the Cedars–Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute and Aptium Oncology — both in Los Angeles.

Related Letters:

Bortezomib plus Melphalan and Prednisone for Multiple Myeloma
Islam A., Ambrus J. L., Avvisati G., Tsubokura M., Kami M., Komatsu T., Miguel J. F. S., van de Velde H., Richardson P. G.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:2613-2614, Dec 11, 2008. Correspondence

This article has been cited by other articles:

• Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., Fisher, R. I. (2009). Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20: 520-525 [Abstract] [Full Text]  
• Islam, A., Ambrus, J. L., Avvisati, G., Tsubokura, M., Kami, M., Komatsu, T., Miguel, J. F. S., van de Velde, H., Richardson, P. G. (2008). Bortezomib plus Melphalan and Prednisone for Multiple Myeloma. NEJM 359: 2613-2614 [Full Text]